Targeting Akt by SC66 triggers GSK-3 mediated apoptosis in colon cancer therapy

BackgroundColon cancer is one of the three common malignant tumors, with lower 5years survival rate. Akt is an important therapeutic target, while SC66 is a novel allosteric AKT inhibitor, which enhances the therapeutic effect in several types of cancer. However, the molecular mechanisms of targeting AKT by SC66 during colon cancer therapy are not well understood.MethodsThe biological role of GSK-3 in colon cancer growth suppression induced by SC66 was detected in vitro and in vivo. Hoechst 33342 and crystal violet staining were used to determine whether targeting AKT affected apoptosis and cell proliferation. The CCK8 assay was utilized to analyze cell viability. The expression levels of Akt, GSK-3, Bax, Bcl-xL, p53 and PUMA were measured by immune blotting. Xenograft mouse model was established to study the antitumor effect of SC66 in vivo.ResultsOur results show that SC66 induced significantly colon cancer cell apoptosis, accompanied with Akt inactivation. After AKT inhibition, activated GSK-3 interacted with Bax directly, leading to Bax oligomerization and activation. Knocking down GSK-3 abrogated SC66-triggered Bax activation and apoptosis, which was enhanced by over-expressed GSK-3. In addition, the expression level of Bcl-xL was down-regulated while p53 had no function during SC66-induced apoptosis. Furthermore, colon cancer growth was suppressed by SC66 therapy in vivo.ConclusionTaken together, these data indicated that the novel small molecule AKT inhibitor SC66 shows visible antitumor effects via the AKT/GSK-3/Bax axis in vitro and in vivo. Our results provide a rational basis for the development of targeting-GSK-3, which may serve as a potential biomarker and yield meaningful benefits for colon cancer patients in the future.